{"id":"doi:10.3390/metabo11020073","kind":"review","title":"Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials","authors":["Mantovani A","Petracca G","Beatrice G","Csermely A","Lonardo A","Targher G"],"author_count":6,"year":2021,"published":"2021-01-27","venue":"Metabolites","cited_by":226,"doi":"10.3390/metabo11020073","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3390/metabo11020073","archive_url":"https://space-kitty.com/papers/doi:10.3390/metabo11020073","updated":null,"pmid":"33513761","pmcid":"PMC7911747","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC7911747/pdf","abstract":"To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Three large electronic databases were systematically searched (up to 15 December 2020) to identify placebo-controlled or active-controlled RCTs using different GLP-1 RAs. We included eleven placebo-controlled or active-controlled phase-2 RCTs (involving a total of 936 middle-aged individuals) that used liraglutide ( n = 6 RCTs), exenatide ( n = 3 RCTs), dulaglutide ( n = 1 RCT) or semaglutide ( n = 1 RCT) to specifically treat NAFLD or NASH, detected by liver biopsy ( n = 2 RCTs) or imaging techniques ( n = 9 RCTs). Compared to placebo or reference therapy, treatment with GLP-1 RAs for a median of 26 weeks was associated with significant reductions in the absolute percentage of liver fat content on magnetic resonance-based techniques (pooled weighted mean difference: -3.92%, 95% confidence intervals (CI) -6.27% to -1.56%) and serum liver enzyme levels, as well as with greater histological resolution of NASH without worsening of liver fibrosis (pooled random-effects odds ratio 4.06, 95% CI 2.52-6.55; for liraglutide and semaglutide only). In conclusion, treatment with GLP-1 RAs (mostly liraglutide and semaglutide) is a promising treatment option for NAFLD or NASH that warrants further investigation.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials\" by Mantovani A, Petracca G, Beatrice G et al., https://doi.org/10.3390/metabo11020073, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[{"slug":"glp1-metabolic","title":"GLP-1 & Incretin Therapies: State of the Field (October 2026)","url":"https://space-kitty.com/dossiers/glp1-metabolic"}]}